Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Return on Capital Employed (2021 - 2025)

SAB Biotherapeutics' Return on Capital Employed history spans 5 years, with the latest figure at 0.29% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 75.0% year-over-year to 0.29%; the TTM value through Dec 2025 reached 0.29%, up 75.0%, while the annual FY2025 figure was 0.5%, 26.0% up from the prior year.
  • Return on Capital Employed reached 0.29% in Q4 2025 per SABSW's latest filing, up from 0.45% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.18% in Q4 2021 to a low of 1.78% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.82%, with a median of 0.79% recorded in 2022.
  • The largest YoY upside for Return on Capital Employed was 75bps in 2025 against a maximum downside of -101bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.18% in 2021, then plummeted by -327bps to 0.79% in 2022, then decreased by -7bps to 0.84% in 2023, then decreased by -25bps to 1.05% in 2024, then soared by 72bps to 0.29% in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Return on Capital Employed are 0.29% (Q4 2025), 0.45% (Q3 2025), and 1.78% (Q2 2025).